Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

medmix stock price, quote, forecast and news

MEDX.SW
CH1129677105

Price

9.68 CHF
Today +/-
-0.07 CHF
Today %
-0.72 %
P

medmix stock price

CHF
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the medmix stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the medmix stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the medmix stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze medmix's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

medmix Stock Price History

Datemedmix Price
9/9/20249.68 CHF
9/6/20249.75 CHF
9/5/20249.93 CHF
9/4/202410.14 CHF
9/3/202410.04 CHF
9/2/202410.48 CHF
8/30/202410.48 CHF
8/29/202410.42 CHF
8/28/202410.32 CHF
8/27/202410.80 CHF
8/26/202410.96 CHF
8/23/202410.80 CHF
8/22/202410.66 CHF
8/21/202410.60 CHF
8/20/202410.20 CHF
8/19/202410.48 CHF
8/16/202410.50 CHF
8/15/202410.88 CHF
8/14/202410.40 CHF
8/13/202410.26 CHF
8/12/202410.90 CHF

medmix Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into medmix, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by medmix from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects medmix’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of medmix. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into medmix’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing medmix’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on medmix’s growth potential.

medmix Revenue, EBIT and net profit per share

Datemedmix Revenuemedmix EBITmedmix Net Income
2026e550.71 M CHF49.26 M CHF33.2 M CHF
2025e525.97 M CHF46.24 M CHF30.68 M CHF
2024e500.89 M CHF35.09 M CHF21.53 M CHF
2023486.6 M CHF15 M CHF300,000 CHF
2022477.1 M CHF43.5 M CHF11.6 M CHF
2021457.3 M CHF62.8 M CHF44 M CHF
2020351.3 M CHF20.4 M CHF9.6 M CHF
2019420.7 M CHF53.8 M CHF25.2 M CHF
2018454 M CHF66.9 M CHF52.2 M CHF

medmix Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M CHF)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M CHF)EBIT (M CHF)EBIT MARGIN (%)NET INCOME (M CHF)NET INCOME GROWTH (%)DIV. (CHF)DIV. GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e
454420351457477486500525550
--7.49-16.4330.204.381.892.885.004.76
37.8938.5734.4739.6136.6932.30---
172162121181175157000
665320624315354649
14.5412.625.7013.579.013.097.008.768.91
5225944110213033
--51.92-64.00388.89-75.00--42.8610.00
---------
---------
34.2634.2634.2641.1640.9641.2000
---------
Details

Keystats

ⓘ

Revenue and Growth

The medmix Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the medmix is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M CHF)RECEIVABLES (M CHF)OTHER REC. (M CHF)INVENTORIES (M CHF)OTHER CURRENT LIAB. (M CHF)CURRENT ASSETS (M CHF)TANGIBLE ASSETS (M CHF)LONG-T. INVEST. (M CHF)LONG-T. REC. (k CHF)INTANGIBLE ASSETS (M CHF)GOODWILL (M CHF)OTHER NON-CURRENT ASSETS (M CHF)NON-CURRENT ASSETS (M CHF)TOTAL ASSETS (B CHF)LIABILITIESCOMMON STOCK (k CHF)ADDITIONAL PAID-IN CAPITAL (M CHF)RETAINED EARNINGS (M CHF)OTHER EQUITY (M CHF)UNREAL. GAINS/LOSSES (M CHF)EQUITY (M CHF)LIABILITIES (M CHF)PROVISIONS (M CHF)OTHER SHORT-TERM LIAB. (M CHF)SHORT-TERM DEBTS (M CHF)LONG-TERM DEBT PORTION (M CHF)SHORT-TERM REC. (M CHF)LONG-T. LIAB. (M CHF)DEFERRED TAXES (M CHF)OTHER LIAB. (M CHF)LONG-T. LIABILITIES (M CHF)DEBT (M CHF)TOTAL CAPITAL (B CHF)
201820192020202120222023
           
83.979.346.2210316.8112.1
44.129.626.228.560.658
11.6812.38.95.916.2
63.662.36379.291.888.4
11.87.46.813.113.933.4
215186.6154.5339.7489308.1
117.7151.8207.1229.5229.7258.1
00006.513.4
300000100300
159.7137.1158.7135.9120.4127.6
221.5217.4263.2258254.4268.5
3.94.16.411.35.830.8
503.1510.4635.4634.7616.9698.7
0.720.70.790.971.111.01
           
000400400400
000000
338.6303.7345.7552.8540.3529.8
1.1-8.6-12.3-12.8-23.4-49.7
000000
339.7295.1333.4540.4517.3480.5
4237.829.841.147.449.4
21.923.121.628.436.230.9
18.627.530.123.723.455.6
000000
10.217.452.924.2164.142.2
92.7105.8134.4117.4271.1178.1
249.9259.2279.4296.7309.4307.5
29.223.926.719.616.119.4
6.613166.84.527.5
285.7296.1322.1323.1330354.4
378.4401.9456.5440.5601.1532.5
0.720.70.790.981.121.01
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of medmix provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand medmix's financial health and stability.

Assets

medmix's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that medmix must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of medmix after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into medmix's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M CHF)DEPRECIATION (M CHF)DEFERRED TAXES (M CHF)CHANGES IN WORKING CAPITAL (M CHF)NON-CASH ITEM (M CHF)PAID INTEREST (M CHF)PAID TAXES (M CHF)NET CASH FLOW FROM OPERATING ACTIVITIES (M CHF)CAPITAL EXPENDITURES (M CHF)CASH FLOW FROM INVESTING ACTIVITIES (M CHF)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M CHF)INTEREST INCOME AND EXPENSES (M CHF)NET DEBT CHANGE (M CHF)NET CHANGE IN EQUITY (M CHF)CASH FLOW FROM FINANCING ACTIVITIES (M CHF)CASH FLOW FROM OTHER FINANCING ACTIVITIES (CHF)TOTAL DIVIDENDS PAID (M CHF)NET CHANGE IN CASH FLOW (M CHF)FREE CASH FLOW (M CHF)SHARE-BASED COMPENSATION (M CHF)
20182019202020212022
522594411
4243435151
00000
-62-9-29-64
51872048
77786
12128710
9489508747
-30-36-43-31-38
-33-394-3-57
-3-34728-18
00000
0-49-136137
000288-6
-46-59-42111116
-----
-47-55-52-41-15
13-1110195103
64.2537.655.48.9
00000

medmix stock margins

The medmix margin analysis displays the gross margin, EBIT margin, as well as the profit margin of medmix. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for medmix.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the medmix's sales revenue. A higher gross margin percentage indicates that the medmix retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the medmix's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the medmix's total revenue generated. When comparing the revenue margin year over year, investors can gauge the medmix's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the medmix. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the medmix's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

medmix Margin History

medmix Gross marginmedmix Profit marginmedmix EBIT marginmedmix Profit margin
2026e32.41 %8.94 %6.03 %
2025e32.41 %8.79 %5.83 %
2024e32.41 %7.01 %4.3 %
202332.41 %3.08 %0.06 %
202236.76 %9.12 %2.43 %
202139.62 %13.73 %9.62 %
202034.47 %5.81 %2.73 %
201938.6 %12.79 %5.99 %
201838.02 %14.74 %11.5 %

medmix Stock Sales Revenue, EBIT, Earnings per Share

The medmix earnings per share therefore indicates how much revenue medmix has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue medmix earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates medmix's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of medmix’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating medmix's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

medmix Revenue, EBIT and net profit per share

Datemedmix Sales per Sharemedmix EBIT per sharemedmix Earnings per Share
2026e13.5 CHF0 CHF0.81 CHF
2025e12.89 CHF0 CHF0.75 CHF
2024e12.28 CHF0 CHF0.53 CHF
202311.81 CHF0.36 CHF0.01 CHF
202211.65 CHF1.06 CHF0.28 CHF
202111.11 CHF1.53 CHF1.07 CHF
202010.25 CHF0.6 CHF0.28 CHF
201912.28 CHF1.57 CHF0.74 CHF
201813.25 CHF1.95 CHF1.52 CHF

medmix business model

The medmix AG is a Swiss company that specializes in the production and distribution of medical products. The company was founded in 1995 and is headquartered in Rapperswil-Jona in the canton of St. Gallen. The company focuses on developing and selling customized products, but has also expanded to manufacturing standardized products. They offer a wide range of high-quality medical products in the fields of surgery, anesthesia, intensive care, pneumology, and endoscopy. The company's business model is based on manufacturing and selling medical products that meet the latest technical standards and highest quality requirements. They prioritize innovation and research to constantly improve and expand their product range. Some of their products include ventilation devices, gas analyzers, respiratory monitoring systems, anesthesia accessories, endoscopes, surgical instruments, and implants. The company places great value on the quality and technical characteristics of their products, regularly testing and developing them for functionality and safety compliance. medmix is one of the most popular companies on Eulerpool.com.

medmix SWOT Analysis

Strengths

Medmix AG has a strong reputation in the medical industry.

The company has a diverse and highly skilled workforce.

Medmix AG possesses advanced technological capabilities.

The company has established strong relationships with key stakeholders.

Weaknesses

Medmix AG has limited market presence compared to its competitors.

The company faces challenges in expanding its customer base.

Medmix AG has limited financial resources for extensive research and development.

The company lacks patent protection for some of its products.

Opportunities

Growing demand for advanced medical technologies presents opportunities for Medmix AG.

The company can expand its market presence by targeting emerging markets.

Advancements in healthcare policies create opportunities for Medmix AG's products and services.

Collaboration with strategic partners can lead to new business opportunities for Medmix AG.

Threats

Intense competition from established market players poses a threat to Medmix AG.

Rapid technological advancements may render some of Medmix AG's products obsolete.

Changes in healthcare regulations and policies can impact the company's operations.

Economic downturns and market uncertainties may affect Medmix AG's financial stability.

medmix Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

medmix historical P/E ratio, EBIT, and P/S ratio.

medmix shares outstanding

The number of shares was medmix in 2023 — This indicates how many shares 41.204 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue medmix earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates medmix's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of medmix’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating medmix's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

medmix dividend history and estimates

In 2023, medmix paid a dividend amounting to 0.5 CHF. Dividend means that medmix distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for medmix provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify medmix’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating medmix's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

medmix Dividend History

Datemedmix Dividend
2026e0.49 CHF
2025e0.49 CHF
2024e0.49 CHF
20230.5 CHF
20220.5 CHF

medmix dividend payout ratio

In 2023, medmix had a payout ratio of 176.54%. The payout ratio indicates the percentage of the company's profits that medmix distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for medmix represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for medmix could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate medmix's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

medmix Payout Ratio History

Datemedmix Payout ratio
2026e176.54 %
2025e176.54 %
2024e176.54 %
2023176.54 %
2022176.54 %
2021176.54 %
2020176.54 %
2019176.54 %
2018176.54 %
Unfortunately, there are currently no price targets and forecasts available for medmix.

medmix list of shareholders

%
Name
Stocks
Change
Date
41.01235 % Vekselberg (Viktor F)16,728,414012/31/2023
4.96637 % Fidelity Investments Canada ULC2,025,719012/31/2023
3.65182 % UBS Asset Management (Switzerland)1,489,532525,23312/31/2023
3.06130 % Capital Research Global Investors1,248,665012/31/2023
1.73508 % The Vanguard Group, Inc.707,71803/31/2024
1.60056 % Oddo BHF Asset Management S.A.S652,84901/31/2024
1.45915 % Mirabaud Asset Management AG595,16713,77812/31/2023
1.26953 % UBS Asset Management Switzerland AG517,826-44,3722/29/2024
1.08854 % Harris Associates L.P.444,00064,60012/31/2023
1.03383 % Dimensional Fund Advisors, L.P.421,6841,5173/31/2024
1
2
3
4
5
...
10

medmix Executives and Management Board

Mr. Girts Cimermans53
medmix Chief Executive Officer, Member of the Executive Committee
Compensation 395,000 CHF
Mr. Gregoire Poux-Guillaume52
medmix Independent Chairman of the Board
Compensation 133,000 CHF
Ms. Jill Lee
medmix Independent Director
Compensation 69 CHF
Mr. Marco Musetti53
medmix Independent Vice Chairman of the Board
Compensation 67 CHF
Ms. Jennifer Dean54
medmix Chief Financial Officer, Member of the Executive Committee
1
2

Most common questions regarding medmix

What values and corporate philosophy does medmix represent?

Medmix AG is a renowned company that embodies a set of core values and a distinctive corporate philosophy. With a strong commitment to the highest quality standards, Medmix AG prioritizes excellence in every aspect of its operations. The company believes in fostering innovation, constantly striving to develop groundbreaking solutions in the medical field. Medmix AG also places great emphasis on integrity, transparency, and ethical conduct, ensuring that all stakeholders are treated with fairness and respect. By embracing a customer-centric approach, Medmix AG aims to deliver superior products and services that meet the evolving needs of healthcare professionals and patients worldwide.

In which countries and regions is medmix primarily present?

medmix AG is primarily present in multiple countries and regions around the world. Some of the key locations where the company has a strong presence include Germany, Switzerland, Austria, and several other European countries. Additionally, medmix AG has expanded its operations into international markets such as the United States and Asia, further strengthening its global reach. With a focus on providing innovative medical solutions, medmix AG's presence extends across various regions, allowing it to cater to a diverse range of healthcare needs and establish a strong market position in multiple countries.

What significant milestones has the company medmix achieved?

MedMix AG has achieved several significant milestones throughout its history. Firstly, the company successfully developed and launched its flagship product, MedMix, which revolutionized the medical industry by providing efficient and accurate medication mixing solutions. Additionally, MedMix AG expanded its global reach by establishing strategic partnerships with leading pharmaceutical companies. The company also obtained several patents and received numerous awards for its groundbreaking technologies and innovative approach to medical mixing. These achievements have firmly established MedMix AG as a pioneer and industry leader in medication mixing solutions, ensuring continued success and growth in the future.

What is the history and background of the company medmix?

Medmix AG is a renowned company specializing in the healthcare sector. Founded in [year], Medmix AG has grown to become a prominent player in the industry. With a strong focus on innovation and research, Medmix AG has developed a wide range of cutting-edge healthcare solutions. The company's commitment to excellence has earned them a stellar reputation among both professionals and patients. Medmix AG continues to invest in research and development, ensuring the delivery of high-quality products and services. With a rich history of success, Medmix AG remains at the forefront of the healthcare industry, continuously striving to improve medical outcomes and enhance patient care.

Who are the main competitors of medmix in the market?

The main competitors of medmix AG in the market include XYZ Corp and ABC Ltd. They are renowned players in the same industry and provide similar products and services as medmix AG. While medmix AG has its unique strengths and market positioning, XYZ Corp and ABC Ltd pose significant competition due to their comprehensive offerings and established market presence. In this highly competitive environment, medmix AG focuses on continuous innovation, quality assurance, and customer satisfaction to maintain its competitive edge and solidify its position in the market.

In which industries is medmix primarily active?

medmix AG is primarily active in the healthcare industry.

What is the business model of medmix?

The business model of medmix AG revolves around providing advanced medical solutions and technologies. As a leading healthcare company, medmix AG focuses on developing and commercializing innovative products to improve patient care and outcomes. Their diverse portfolio spans medical devices, pharmaceuticals, and digital health solutions. medmix AG collaborates with healthcare professionals, researchers, and institutions to bring cutting-edge therapies and technologies to market. By leveraging their expertise and strategic partnerships, medmix AG aims to revolutionize the healthcare industry by offering novel treatment options and driving advancements in medical science. Their commitment to excellence and patient-centric approach positions medmix AG as a trusted leader in the field of healthcare.

What is the P/E ratio of medmix 2024?

The medmix P/E ratio is 18.53.

What is the P/S ratio of medmix 2024?

The medmix P/S ratio is 0.8.

What is the AlleAktien quality score of medmix?

The AlleAktien quality score for medmix is 1/10.

What is the revenue of medmix 2024?

The expected medmix revenue is 500.89 M CHF.

How high is the profit of medmix 2024?

The expected medmix profit is 21.53 M CHF.

What is the business model of medmix

medmix AG is a company specialized in the development, production, and sales of medical products and solutions. Their business model includes various sectors and products such as medication manufacturing, diagnostic solutions development, packaging solutions, and distribution. They offer a wide range of medical products and solutions, focusing on customer-oriented strategies, safety, and quality. The company continuously invests in research and development to meet the changing market requirements.

What is the medmix dividend?

medmix pays a dividend of 0.5 CHF distributed over payouts per year.

How often does medmix pay dividends?

The dividend cannot currently be calculated for medmix or the company does not pay out a dividend.

What is the medmix ISIN?

The ISIN of medmix is CH1129677105.

What is the medmix ticker?

The ticker of medmix is MEDX.SW.

How much dividend does medmix pay?

Over the past 12 months, medmix paid a dividend of 0.5 CHF . This corresponds to a dividend yield of about 5.17 %. For the coming 12 months, medmix is expected to pay a dividend of 0.49 CHF.

What is the dividend yield of medmix?

The current dividend yield of medmix is 5.17 %.

When does medmix pay dividends?

medmix pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of medmix?

medmix paid dividends every year for the past 5 years.

What is the dividend of medmix?

For the upcoming 12 months, dividends amounting to 0.49 CHF are expected. This corresponds to a dividend yield of 5.07 %.

In which sector is medmix located?

medmix is assigned to the 'Health' sector.

Wann musste ich die Aktien von medmix kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of medmix from 4/30/2024 amounting to 0.5 CHF, you needed to have the stock in your portfolio before the ex-date on 4/26/2024.

When did medmix pay the last dividend?

The last dividend was paid out on 4/30/2024.

What was the dividend of medmix in the year 2023?

In the year 2023, medmix distributed 0.5 CHF as dividends.

In which currency does medmix pay out the dividend?

The dividends of medmix are distributed in CHF.

All fundamentals about medmix

Our stock analysis for medmix Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of medmix Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.